Clinical Trials and Research

Fujirebio’s Lumipulse NfL, pTau 217 Assays Receive Health Canada Licences

These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions ...

Roche’s Columvi Added to Singapore’s Subsidised Drug Lists for DLBCL

This underscores an urgent need for a broader range of novel and efficacious treatment options...

Vesalio’s enVast thrombectomy trial meets primary endpoint in large-thrombus STEMI

The randomised NATURE trial found that enVast-assisted mechanical thrombectomy reduced infarct size compared with conventional PCI in STEMI patients with a large thrombus burden....

Perlove Medical’s PLX C22 Series C-arm Completes China Product Registration Update

The C22 features a 5 kW/110 kHz generator, with pulsed fluoroscopy of up to 40 mA and 30 frames per second (fps)...

Pulnovo enrols first US patients in PULSE-LHD pulmonary artery denervation trial

The FDA IDE study is evaluating pulmonary artery denervation in patients with combined pre- and post-capillary pulmonary hypertension associated with left heart disease....

Pulnovo Medical Enrolls First Patients in FDA IDE Trial of PADN for Pulmonary Hypertension

The milestone marks the initiation of the IDE study, representing a major step forward in the clinical advancement of the PADN procedure...

Galvanize Therapeutics reports new evidence on immune effects of Aliya pulsed electric field therapy

New peer-reviewed clinical findings suggest pulsed electric field ablation may trigger organised immune responses within tumours in addition to its local tissue-ablation effects....

CanSinoBIO Advances Five-Component Pertussis Booster Vaccine in China

Pertussis is a highly contagious acute respiratory infectious disease caused by Bordetella pertussis...

Everest Medicines Announces NMPA Acceptance of BLA for LEROCHOL(R)

The on-schedule acceptance underscores the Company's disciplined execution of its clinical and regulatory strategy...

Ascendis Pharma’s Combination Therapy Shows Durable Growth in Children with Achondroplasia

Treatment with the combination of once-weekly TransCon CNP and once-weekly TransCon hGH continued to demonstrate durable growth in children with achondroplasia...